Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).
作者： Moshe Chaim Ornstein , Andrew J. Stephenson , Paul Elson , Allison Janine Tyler , Pam Profusek
DOI: 10.1200/JCO.2016.34.15_SUPPL.5071
关键词:
摘要: 5071Background: Management of HRPCa remains a clinical challenge. Novel AR inhibitors are now standard care in castration-resistant prostate cancer (CRPC) and could potentially impact outcome in...
sci-hub.st 参考文章(0)